Jennifer Zachary
Director; EVP, General Counsel · 6 filings · Latest: Aug 12, 2026
Merck & Co., Inc.
REGENXBIO Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
MRK | Jennifer Zachary | EVP, General Counsel | Aug 12, 2026 | Sale | $133.46 | 80,315 | $10.7M | 45,509.254 | |
MRK | Jennifer Zachary | EVP, General Counsel | Aug 12, 2026 | Option Exercise | $109.78 | 54,927 | $6.0M | 125,824.254 | |
MRK | JENNIFER L ZACHARY | — | Aug 12, 2026 | Proposed Sale | $133.46 | 80,315 | $10.7M | — | |
MRK | Jennifer Zachary | EVP, General Counsel | Apr 29, 2026 | Option Exercise | $110.03 | 2,951 | $324.7K | 72,351.254 | |
MRK | JENNIFER ZACHARY | — | Feb 9, 2026 | Proposed Sale | $119.15 | 121,573 | $14.5M | — | |
MRK | Jennifer Zachary | EVP, General Counsel | Feb 9, 2026 | Sale | $119.15 | 121,573 | $14.5M | 68,915.671 | |
MRK | Jennifer Zachary | EVP, General Counsel | Feb 9, 2026 | Option Exercise | $119.15 | 121,573 | $14.5M | 107,750.671 |